Results 251 to 260 of about 318,819 (293)

Adoptive cell therapy and cytokine release syndrome

Mediastinum
Sivapiromrat, Alisa K., Rajan, Arun, McAdams, Meredith   +2 more
openaire   +1 more source

Operationalization and Use of Bispecific T-Cell-Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management. [PDF]

J Adv Pract Oncol
Donnellan W, Lin SW, Abbas J, Berdeja JG, Cassoli L, Chandler JC, Flores B, Hall S, Ravelo A, Masaquel A, Patterson S, Peng E, Todd A, Traughber C, Raff L.   +14 more
europepmc   +1 more source

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.

Blood
Abboud R, Schroeder MA, Rettig MP, Jayasinghe RG, Gao F, Eisele J, Gehrs L, Ritchey J, Choi J, Abboud CN, Pusic I, Jacoby M, Westervelt P, Christopher M, Cashen A, Ghobadi A, Stockerl-Goldstein K, Uy GL, DiPersio JF.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Druggable Targets in Cytokine Release Syndromes

Clinical Cancer Research, 2023
Summary Bispecific T-cell engagers and chimeric antigen receptor T cells share the problem of eliciting acute systemic inflammation episodes known as cytokine release syndrome. Knowledge on the sequential waves of cytokines that can be neutralized with clinically available agents is crucial to prevent or treat this condition without ...
Carlos Luri-Rey, Iñaki Eguren-Santamaria, Ignacio Matos, Pedro Berraondo, Ignacio Melero   +4 more
openaire   +2 more sources

Cytokine Release Syndrome Biology and Management

The Cancer Journal, 2021
Abstract The successful application of chimeric antigen receptor (CAR) T cells for the treatment of relapsed and refractory B-cell malignancies has ushered in a new frontier for the immunotherapy of cancer. Despite its successes, CAR T-cell therapy presents several challenges.
Dustin A, Cobb, Daniel W, Lee
openaire   +2 more sources

Modeling cytokine release syndrome

Nature Medicine, 2018
Complete leukemic responses to chimeric antigen receptor–modified T cells are invariably accompanied by severe toxicity. Recently developed animal models allow mechanistic dissection and prevention of toxicity without loss of therapeutic benefit.
Cliona, Rooney, Tim, Sauer
openaire   +2 more sources

Therapeutics for the Management of Cytokine Release Syndrome in COVID-19

Current Topics in Medicinal Chemistry, 2023
Abstract: Coronavirus disease (COVID-19) is the greatest pandemic of this era and has affected more than 10 million people across 213 nations. However, the etiology, management, and treatment of COVID-19 remain unknown. A better understanding of the novel virus would help in developing accurate diagnostic methods and efficacious drugs for the ...
Jitendra Kumar Sinha, Rakesh Bhaskar, Shampa Ghosh, Shantanu Durgvanshi, Sung Soo Han   +4 more
openaire   +2 more sources

Cytokine Release Syndrome in Pathogenesis and Treatment of COVID-19

Current Pharmaceutical Design, 2022

Tao, Hu, Chi Hin, Cho
openaire   +2 more sources